Modeling Long-Term Cost-Effectiveness of Sitagliptin and SGLT2i Combination Therapy for the Treatment of Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1247-p
Abstract: Clinical benefits of dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) combination therapy have been demonstrated through clinical trials; however, there is limited understanding of economic benefits of sequential use of these therapies.… read more here.
Keywords: self merck; treatment; merck inc; cost ... See more keywords
Distance from Glycemic Target at the Time of Add-On Initiation in Patients with Type 2 Diabetes (T2D) Failing Metformin Monotherapy in the United States
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1628-p
Abstract: While it is known that a substantial proportion of U.S. patients with T2D are not at glycemic target, the distance to glycemic target has not been adequately characterized, especially at the time of add-on initiation.… read more here.
Keywords: self merck; employee; merck inc; time ... See more keywords
Conformance to Type 2 Diabetes (T2D) Guidelines in a Large U.S. Health Plan
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1658-p
Abstract: Almost half of U.S. T2D patients (pts) have suboptimal glycemic control (A1c ≥7%). One factor that may be associated with this is clinical inertia related to physician/patient actions or lack of “conformance” to guidelines. We… read more here.
Keywords: conformance; self merck; conformance type; merck inc ... See more keywords
1119-P: Efficacy and Safety of Sitagliptin (SITA) Compared with Dapagliflozin (DAPA) in People ≥65 Years Old with T2D
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1119-p
Abstract: In the U.S., ~45% of patients with T2D are ≥65 years old, of whom ~50% have mild renal insufficiency (eGFR ≥60 and Treatment groups were well-balanced at baseline (mean A1C [%] = 7.7/7.7, mean eGFR… read more here.
Keywords: merck inc; self merck; employee self;
1149-P: A1C Goal Attainment after Metformin (MET) Uptitration With and Without Sitagliptin (SITA): Impact of Baseline and Target A1C
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1149-p
Abstract: MET is generally recommended as the initial AHA for T2D, but many patients do not achieve glycemic goal at an initial, sub-maximal dose (500-1000 mg/day) and should intensify therapy. Typically, MET dose is first maximized,… read more here.
Keywords: merck inc; a1c goal; self merck; goal ... See more keywords
1197-P: Two-Year Effects of Ertugliflozin on Renal Function
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1197-p
Abstract: 2 RCT evaluating ertugliflozin 5 mg (E5, n=652), 15 mg (E15, n=640) vs. non-ertugliflozin (NE, glimepiride or placebo, n=644) in T2D patients were pooled to evaluate effects on eGFR (MDRD) and albuminuria (UACR, geometric mean… read more here.
Keywords: inc; merck inc; self merck; employee self ... See more keywords
2334-PUB: Evolution of the Designs of the Sitagliptin (SITA) Pediatric Clinical Studies
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2334-pub
Abstract: Approved antihyperglycemic therapies for pediatric patients with T2D are currently limited to metformin (MET) and insulin. SITA is being evaluated in 3 studies in patients 10-17 years of age with T2D: SITA as initial oral… read more here.
Keywords: employee; merck inc; self merck; inc ... See more keywords
35-LB: Response to Anti-VEGF Therapy in a Nonhuman Primate Model of Diabetic Macular Edema
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-35-lb
Abstract: Diabetic macular edema (DME) is one manifestation of diabetic retinopathy (DR), where fluids leak from the retinal vessels into the centre of the macula, causing swelling and blurred vision. VEGF inhibitors (e.g., ranibizumab), have demonstrated… read more here.
Keywords: none; diabetic macular; vegf; employee ... See more keywords